These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 21508394

  • 21. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.
    Winter WE, Maxwell GL, Tian C, Sundborg MJ, Rose GS, Rose PG, Rubin SC, Muggia F, McGuire WP, Gynecologic Oncology Group.
    J Clin Oncol; 2008 Jan 01; 26(1):83-9. PubMed ID: 18025437
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. [Profiling of serum tumor markers in patients with epithelial ovarian carcinoma].
    Dong L, Li XP, Cui H, Wang JL, Wei LH, Zhao Y, Wang SJ, Wang Y, Sun XL, Liang XD, Li Y.
    Zhonghua Fu Chan Ke Za Zhi; 2009 Feb 01; 44(2):121-5. PubMed ID: 19570423
    [Abstract] [Full Text] [Related]

  • 27. Impact of Preoperative Serum Levels of CA 125 on Epithelial Ovarian Cancer Survival.
    Pradjatmo H, Pradjatmo H.
    Asian Pac J Cancer Prev; 2016 Feb 01; 17(4):1881-6. PubMed ID: 27221870
    [Abstract] [Full Text] [Related]

  • 28. Circulating prolactin levels and risk of epithelial ovarian cancer.
    Clendenen TV, Arslan AA, Lokshin AE, Liu M, Lundin E, Koenig KL, Berrino F, Hallmans G, Idahl A, Krogh V, Lukanova A, Marrangoni A, Muti P, Nolen BM, Ohlson N, Shore RE, Sieri S, Zeleniuch-Jacquotte A.
    Cancer Causes Control; 2013 Apr 01; 24(4):741-8. PubMed ID: 23378139
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Clinical significance of RCAS1 as a biomarker of uterine cancer.
    Sonoda K, Miyamoto S, Hirakawa T, Yagi H, Yotsumoto F, Nakashima M, Watanabe T, Nakano H.
    Gynecol Oncol; 2006 Dec 01; 103(3):924-31. PubMed ID: 16842844
    [Abstract] [Full Text] [Related]

  • 31. Identification of metabolic biomarkers to diagnose epithelial ovarian cancer using a UPLC/QTOF/MS platform.
    Fan L, Zhang W, Yin M, Zhang T, Wu X, Zhang H, Sun M, Li Z, Hou Y, Zhou X, Lou G, Li K.
    Acta Oncol; 2012 Apr 01; 51(4):473-9. PubMed ID: 22283470
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Clinical outcome of tertiary surgical cytoreduction in patients with recurrent epithelial ovarian cancer.
    Fotopoulou C, Richter R, Braicu IE, Schmidt SC, Neuhaus P, Lichtenegger W, Sehouli J.
    Ann Surg Oncol; 2011 Jan 01; 18(1):49-57. PubMed ID: 20697821
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α2b in patients with recurrent epithelial ovarian cancer.
    Dijkgraaf EM, Santegoets SJ, Reyners AK, Goedemans R, Wouters MC, Kenter GG, van Erkel AR, van Poelgeest MI, Nijman HW, van der Hoeven JJ, Welters MJ, van der Burg SH, Kroep JR.
    Ann Oncol; 2015 Oct 01; 26(10):2141-9. PubMed ID: 26216383
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. IL17a and IL21 combined with surgical status predict the outcome of ovarian cancer patients.
    Chen YL, Chou CY, Chang MC, Lin HW, Huang CT, Hsieh SF, Chen CA, Cheng WF.
    Endocr Relat Cancer; 2015 Oct 01; 22(5):703-11. PubMed ID: 26150382
    [Abstract] [Full Text] [Related]

  • 38. Agreement for tumor grade of ovarian carcinoma: analysis of archival tissues from the surveillance, epidemiology, and end results residual tissue repository.
    Matsuno RK, Sherman ME, Visvanathan K, Goodman MT, Hernandez BY, Lynch CF, Ioffe OB, Horio D, Platz C, Altekruse SF, Pfeiffer RM, Anderson WF.
    Cancer Causes Control; 2013 Apr 01; 24(4):749-57. PubMed ID: 23378140
    [Abstract] [Full Text] [Related]

  • 39. Is there a correlation between tumor marker panel and tumor size and histopathology in well staged patients with borderline ovarian tumors?
    Ayhan A, Guven S, Guven ES, Kucukali T.
    Acta Obstet Gynecol Scand; 2007 Apr 01; 86(4):484-90. PubMed ID: 17486473
    [Abstract] [Full Text] [Related]

  • 40. Modified radical hysterectomy versus extrafascial hysterectomy in the treatment of stage I endometrial cancer: results from the ILIADE randomized study.
    Signorelli M, Lissoni AA, Cormio G, Katsaros D, Pellegrino A, Selvaggi L, Ghezzi F, Scambia G, Zola P, Grassi R, Milani R, Giannice R, Caspani G, Mangioni C, Floriani I, Rulli E, Fossati R.
    Ann Surg Oncol; 2009 Dec 01; 16(12):3431-41. PubMed ID: 19834767
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.